Is CHEST PAIN a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed CHEST PAIN.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 29 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported CHEST PAIN to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and CHEST PAIN. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause CHEST PAIN, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes CHEST PAIN. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if CHEST PAIN ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing CHEST PAIN: 29
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where CHEST PAIN is a reported side effect: 0.8711%

FDA reports of any drug causing CHEST PAIN : 77121
Average percentage for all medicated patients where CHEST PAIN is reported as a complication: 0.4833%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with CHEST PAIN:

VIOXX (17356 patients)
ASPIRIN (9213 patients)
FOSAMAX (6884 patients)
LIPITOR (4032 patients)
NEXIUM (3886 patients)
SEROQUEL (3659 patients)
HEPARIN SODIUM INJECTION (3475 patients)
PLAVIX (3358 patients)
LISINOPRIL (3074 patients)
LASIX (2995 patients)
YAZ (2787 patients)
SYNTHROID (2743 patients)
PREDNISONE (2688 patients)
REMICADE (2484 patients)
ATENOLOL (2421 patients)
YASMIN (2391 patients)
COUMADIN (2385 patients)
PRILOSEC (2383 patients)
ZOMETA (2382 patients)
CELEBREX (2379 patients)
ALBUTEROL (2290 patients)
ZOCOR (2283 patients)
XANAX (2229 patients)
NEURONTIN (2200 patients)
TOPROL-XL (2142 patients)
NORVASC (2103 patients)
SIMVASTATIN (2096 patients)
AVANDIA (2095 patients)
PROTONIX (2081 patients)
HUMIRA (2079 patients)
AMBIEN (2052 patients)
NITROGLYCERIN (2008 patients)
ZOLOFT (1996 patients)
OMEPRAZOLE (1967 patients)
FUROSEMIDE (1952 patients)
PREVACID (1949 patients)
HYDROCHLOROTHIAZIDE (1925 patients)
DIGOXIN (1886 patients)
FOLIC ACID (1846 patients)
IBUPROFEN (1786 patients)
VICODIN (1698 patients)
METHOTREXATE (1696 patients)
ACETAMINOPHEN (1604 patients)
FORTEO (1555 patients)
PREMARIN (1540 patients)
PAXIL (1535 patients)
ADVAIR DISKUS 100/50 (1510 patients)
CRESTOR (1490 patients)
AREDIA (1438 patients)
LEXAPRO (1436 patients)
AVONEX (1423 patients)
LEVOTHYROXINE SODIUM (1407 patients)
ATIVAN (1399 patients)
CYMBALTA (1366 patients)
PERCOCET (1362 patients)
POTASSIUM CHLORIDE (1350 patients)
DIOVAN (1347 patients)
METFORMIN HCL (1344 patients)
CHANTIX (1327 patients)
ENBREL (1322 patients)
OXYCONTIN (1301 patients)
VITAMIN D (1296 patients)
SINGULAIR (1267 patients)
METOPROLOL TARTRATE (1262 patients)
LEVAQUIN (1252 patients)
ACCUTANE (1241 patients)
LYRICA (1225 patients)
GLUCOPHAGE (1208 patients)
PROZAC (1193 patients)
LORAZEPAM (1164 patients)
[THERAPY UNSPECIFIED] (1154 patients)
COREG (1136 patients)
ZOFRAN (1118 patients)
LANTUS (1112 patients)
WARFARIN SODIUM (1090 patients)
GABAPENTIN (1088 patients)
TYLENOL (CAPLET) (1086 patients)
LORTAB (1074 patients)
ZYPREXA (1069 patients)
METOPROLOL (1064 patients)
CLONAZEPAM (1044 patients)
ALLOPURINOL (1042 patients)
TYSABRI (1042 patients)
DEXAMETHASONE (1035 patients)
SPIRIVA (1022 patients)
PREDNISONE TAB (1017 patients)
EFFEXOR (1007 patients)
ZANTAC (1003 patients)
MORPHINE (990 patients)
INSULIN (978 patients)
CALCIUM (970 patients)
WELLBUTRIN (966 patients)
ZYRTEC (948 patients)
ALPRAZOLAM (941 patients)
BONIVA (932 patients)
FLEXERIL (931 patients)
AMLODIPINE (920 patients)
BEXTRA (911 patients)
DIANEAL (909 patients)
ZELNORM (909 patients)
KLONOPIN (899 patients)
DURAGESIC-100 (896 patients)
LOPRESSOR (888 patients)
MULTI-VITAMIN (874 patients)
AMOXICILLIN (862 patients)
CELEXA (862 patients)
BYETTA (848 patients)
ALLEGRA (838 patients)
OXYCODONE HCL (834 patients)
TYLENOL (833 patients)
VALIUM (822 patients)
BENADRYL (821 patients)
NAPROXEN (819 patients)
ACTOS (816 patients)
ALTACE (816 patients)
MULTI-VITAMINS (815 patients)
COZAAR (814 patients)
ASCORBIC ACID (809 patients)
PREDNISOLONE (806 patients)
PEPCID (786 patients)
TRAZODONE HCL (780 patients)
VITAMIN E (777 patients)
DECADRON (759 patients)
RANITIDINE (757 patients)
REGLAN (751 patients)
SPIRONOLACTONE (742 patients)
DIAZEPAM (737 patients)
TRAMADOL HCL (734 patients)
LOVENOX (728 patients)
SANDOSTATIN LAR (723 patients)
ZITHROMAX (718 patients)
CLARITIN (715 patients)
CLONIDINE (711 patients)
ACTONEL (705 patients)
ZETIA (704 patients)
MOTRIN (701 patients)
HEPARIN SODIUM (701 patients)
RAMIPRIL (699 patients)
FLONASE (699 patients)
COLACE (672 patients)
ULTRAM (662 patients)
HEPARIN (658 patients)
EXJADE (653 patients)
GLIPIZIDE (652 patients)
ACIPHEX (650 patients)
GLYBURIDE (649 patients)
PRAVACHOL (648 patients)
IMDUR (646 patients)
PRADAXA (638 patients)
COMPAZINE (636 patients)
METFORMIN (633 patients)
FISH OIL (633 patients)
FLOMAX (631 patients)
CIPROFLOXACIN (630 patients)
DILAUDID (626 patients)
ALENDRONATE SODIUM (626 patients)
FENTANYL (625 patients)
TRICOR (624 patients)
REVLIMID (623 patients)
ENALAPRIL MALEATE (611 patients)
CARVEDILOL (604 patients)
TOPAMAX (601 patients)
RISPERDAL (599 patients)
NIASPAN (598 patients)
ELAVIL (597 patients)
REBIF (596 patients)
HYDROCODONE BITARTRATE (594 patients)
CLOZARIL (593 patients)
CALCIUM CARBONATE (592 patients)
CARBOPLATIN (591 patients)
VITAMIN B-12 (584 patients)
CARDIZEM (574 patients)
SYMBICORT (574 patients)
AVELOX (568 patients)
FLUOROURACIL (567 patients)
VYTORIN (566 patients)
KLOR-CON (565 patients)
MORPHINE SULFATE (561 patients)
ZESTRIL (559 patients)
METOPROLOL SUCCINATE (556 patients)
FOSAMAX PLUS D (551 patients)
TRACLEER (547 patients)
HUMALOG (546 patients)
AMITRIPTYLINE HCL (546 patients)
COMBIVENT (545 patients)
CEPHALEXIN (545 patients)
LEVOXYL (533 patients)
PROMETHAZINE (525 patients)
SOMA (523 patients)
TEMAZEPAM (521 patients)
RIBAVIRIN (519 patients)
GILENYA (516 patients)
LANSOPRAZOLE (514 patients)
BETASERON (511 patients)
DROSPIRENONE AND ETHINYL ESTRADIOL (510 patients)
HYDROCODONE (508 patients)
VIAGRA (505 patients)
PHENERGAN (504 patients)
VELCADE (504 patients)
VERAPAMIL (501 patients)
DEPAKOTE (501 patients)
EFFEXOR XR (499 patients)
BACLOFEN (495 patients)
ISOSORBIDE MONONITRATE (495 patients)
NUVARING (491 patients)
VITAMINS (UNSPECIFIED) (490 patients)
POTASSIUM (489 patients)
PANTOPRAZOLE (486 patients)
IMITREX (486 patients)
CIPRO (484 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about CHEST PAIN and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.